Beam Therapeutics Valeur d'entreprise
Quel est le Valeur d'entreprise de Beam Therapeutics?
Le Valeur d'entreprise de Beam Therapeutics Inc. est $2.24B
Quelle est la définition de Valeur d'entreprise?
La valeur d'entreprise est une mesure de la valeur marchande totale d'une entreprise. Il correspond à la capitalisation boursière avec la dette, les intérêts minoritaires et les actions privilégiées moins la trésorerie et les équivalents de trésorerie totaux.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Valeur d'entreprise des entreprises dans Health Care secteur sur NASDAQ par rapport à Beam Therapeutics
Que fait Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Entreprises avec valeur d'entreprise similaire à Beam Therapeutics
- Stepan Co a Valeur d'entreprise de $2.23B
- Biffa Plc a Valeur d'entreprise de $2.24B
- Minmetals Land a Valeur d'entreprise de $2.24B
- Morneau Shepell a Valeur d'entreprise de $2.24B
- Kajaria Ceramics a Valeur d'entreprise de $2.24B
- Polar Capital Technology Trust Plc a Valeur d'entreprise de $2.24B
- Beam Therapeutics a Valeur d'entreprise de $2.24B
- InnoCare Pharma a Valeur d'entreprise de $2.24B
- Global Blue AG a Valeur d'entreprise de $2.24B
- Consolidated Communications Inc a Valeur d'entreprise de $2.24B
- Brookfield Asset Management Re a Valeur d'entreprise de $2.24B
- Indivior PLC a Valeur d'entreprise de $2.25B
- Rail Vikas Nigam a Valeur d'entreprise de $2.25B